ClinicaliQ Trial Snapshot
- Convergent Ablation Plus Left Atrial Appendage Isolation for the Treatment of Persistent Atrial Fibrillation — Recruiting • Non-phase study • Cardiology / Cardiovascular • NCT06165510.
- What is being tested: Convergent ablation (combining epicardial and endocardial approaches) plus left atrial appendage isolation using the LARIAT procedure, compared to standard endocardial catheter ablation alone in long-standing persistent atrial fibrillation.
- Patient eligibility overview: Adults with long-standing persistent atrial fibrillation (typically AF duration >1 year, refractory to antiarrhythmic drugs or cardioversion) who are candidates for invasive rhythm control procedures.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
A randomised controlled clinical trial to assess efficacy of convergent ablation with the LARIAT procedure, as compared to standard endocardial catheter ablation in patients with long-standing persistent atrial fibrillation (AF).
Eligibility Snapshot
- : * Age > 18 years; < 80 years * Persistent AF > 1-year duration * Left atrium size < 6cm * Pts should be able to provide written informed consent.
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.